Treatment design and post-implant dosimetric evaluation were carried out in accordance with the latest American Medical Association Task Group 43 protocols and Variseed version 7.1 (Varian Medical Systems, Palo Alto, CA, USA). For post-implantation dose measurements, computed tomography (CT) and magnetic resonance imaging (MRI) were carried out 1 month from LDR-BT. A CT with a 16- or 64-detector array CT scanner (LightSpeed Ultra 16/Discovery CT 750 HD; GE Healthcare, Milwaukee, WI, USA) was used [21 (link)]. Also, an MRI using a 5-channel SENSE cardiac coil was performed in easy-breathing conditions using a slice thickness of 3 mm and no cross-gap (Intera Achieva 1.5 T/Intra Achieva Nova Dual 1.5 T Pulsar: Philips Medical Systems, Philips Medical Systems, Eindhoven, The Netherlands) [21 (link)]. In this study, the following dosimetric parameters were evaluated: the minimum percentage of the prostate gland received at 90% (D90), the percentage of the PV receiving 100% of the specified minimum peripheral dose (V100), the percentage of the rectal volume receiving 100% of the specified dose (RV100), and the biologically effective dose (BED).
Intera achieva 1.5 t intra achieva nova dual 1.5 t pulsar
Manufactured by Philips
The Intera Achieva 1.5 T and Intra Achieva Nova Dual 1.5 T Pulsar are Magnetic Resonance Imaging (MRI) systems produced by Philips. These systems generate high-quality images by using a strong magnetic field and radio waves to visualize the body's internal structures. They provide detailed information about the body's anatomy and can be used for various medical applications.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using intera achieva 1.5 t intra achieva nova dual 1.5 t pulsar
1
Post-Implant Dosimetric Evaluation in LDR-BT
2
Post-Implant Dosimetry for Low-Dose-Rate Brachytherapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Treatment planning and post-implant dosimetry were performed using the latest American Association of Physicians in Medicine Task Group 43 formalism and Variseed version 7.1 (Varian Medical Systems, Palo Alto, CA, USA). A post-implant dosimetric study using computed tomography (CT) and magnetic resonance imaging (MRI) was performed 1 month after LDR-BT. CT was performed using a CT scanner with a 16 or 64 detector array (LightSpeed Ultra 16/Discovery CT 750 HD; GE Healthcare, Milwaukee, WI, USA), and MRI under respiratory depression was performed using a five-channel SENSE cardiac coil with a slice thickness of 3 mm and no cross-gap (Intera Achieva 1.5 T/Intra Achieva Nova Dual 1.5 T Pulsar; Philips Medical Systems, Eindhoven, The Netherlands). The dosimetric parameters analyzed in this study were the biological effective dose (BED), minimum dose received by 90% of the target volume (D90), percentage of target volume receiving at least 100% of the prescribed dose (V100), minimum dose received by 30% of the urethral volume (UD30), and rectal volume receiving 100% of the prescribed dose (RV100).
3
Dosimetric Evaluations of LDR-BT
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Therapeutic planning and post-implant dosimetric evaluations were performed using the updated American Association of Physicists in Medicine Task Group 43 protocol and VariSeed version 7.1 (Varian Medical Systems, Palo Alto, CA, USA). A post-implant dosimetric study using computed tomography (CT) and magnetic resonance imaging (MRI) was performed one month following LDR-BT. CT was performed using a CT scanner with 16 or 64 detector arrays (LightSpeed Ultra 16/Discovery CT 750 HD; GE Healthcare, Milwaukee, WI, USA).18 (link) MRI was performed using a 5-channel SENSE cardiac coil under easy breathing with a slice thickness of 3 mm and no intersectional gap (Intera Achieva 1.5 T/Intra Achieva Nova Dual 1.5 T Pulsar; Philips Medical Systems, Eindhoven, The Netherlands).18 (link) The dosimetric parameters analyzed in this study were the minimal percentage of the dose received by 90% of the prostate gland (D90), the percentage of PV receiving 100% of the prescribed minimal peripheral dose (V100), the rectal volume receiving 100% of the prescribed dose (RV100), and BED.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!